Company profile: Gain Therapeutics

1.1 - Company Overview

Gain Therapeutics

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of pharmacological chaperone therapeutics for rare metabolic disorders and neurodegenerative diseases. Offers Magellan, an AI-supported 3D structural biology platform using supercomputer-powered models to identify novel allosteric binding sites, and allosteric protein regulation modalities. Pipeline includes GT-02287, a small-molecule for GBA-Parkinson’s disease, in Phase I.

Products and services

Allosteric Protein Regulation: Pathology-driven therapeutics that modulate protein function by stabilization, destabilization, degradation, inhibition, or activation to address rare metabolic disorders and misfolding mutations
GT-02287: A clinical-stage, small-molecule candidate targeting GBA-Parkinson’s disease and other neurodegenerative indications, engineered to stabilize misfolding mutations and restore protein's enzymatic activity
Magellan™: An AI-driven discovery platform leveraging 3D structural biology and supercomputer-powered models to identify novel allosteric binding sites on disease-implicated proteins

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Gain Therapeutics

Azafaros

HQ: The Netherlands Website

Description: Provider of oral azasugar-based therapeutic agents targeting rare lysosomal storage disorders, including the investigational small molecule nizubaglustat for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. Offers the PRONTO natural history study and the RAINBOW clinical study evaluating nizubaglustat, plus an expanded access policy for AZ-3102 limited to clinical trial participation.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Azafaros company profile →

Zacharon Pharmaceuticals

HQ: United States Website

Description: Provider of glycobiology-driven therapeutics targeting glycans for lysosomal storage diseases, including MPS I, II, and III, ganglioside inhibitor programs, and other lysosomal storage disease programs, plus Sensi-Pro clinical diagnostic analyzing glycans for disease diagnosis and monitoring.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Zacharon Pharmaceuticals company profile →

Synageva BioPharma

HQ: United States Website

Description: Provider of novel, next generation and follow on protein therapeutics developed and commercialized using the proprietary Synageva Expression Platform (SEPTM).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Synageva BioPharma company profile →

Pharming

HQ: The Netherlands Website

Description: Provider of protein replacement therapies and precision medicines, including Joenja (leniolisib), an oral, selective PI3Kδ inhibitor approved to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Pharming company profile →

Wave Life Sciences

HQ: United States Website

Description: Provider of clinical-stage RNA medicines spanning RNA editing, antisense oligonucleotides, and RNA interference. Pipeline includes WVE-006 for alpha-1 antitrypsin deficiency, WVE-N531 for Duchenne muscular dystrophy, WVE-003 targeting the huntingtin gene to lower mutant huntingtin, and an INHBE program for obesity and metabolic disorders, advanced via the PRISM platform.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Wave Life Sciences company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Gain Therapeutics

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Gain Therapeutics

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Gain Therapeutics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Gain Therapeutics's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Gain Therapeutics

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Gain Therapeutics's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Gain Therapeutics's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Gain Therapeutics

4.2 - Public trading comparable groups for Gain Therapeutics

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Gain Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Gain Therapeutics

What does Gain Therapeutics do?

Gain Therapeutics is a provider of pharmacological chaperone therapeutics for rare metabolic disorders and neurodegenerative diseases. Offers Magellan, an AI-supported 3D structural biology platform using supercomputer-powered models to identify novel allosteric binding sites, and allosteric protein regulation modalities. Pipeline includes GT-02287, a small-molecule for GBA-Parkinson’s disease, in Phase I.

Who are Gain Therapeutics's competitors?

Gain Therapeutics's competitors and similar companies include Azafaros, Zacharon Pharmaceuticals, Synageva BioPharma, Pharming, and Wave Life Sciences.

Where is Gain Therapeutics headquartered?

Gain Therapeutics is headquartered in United States.

How many employees does Gain Therapeutics have?

Gain Therapeutics has 1,000 employees 🔒.

When was Gain Therapeutics founded?

Gain Therapeutics was founded in 2010 🔒.

What sector and industry vertical is Gain Therapeutics in?

Gain Therapeutics is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Gain Therapeutics

Who are the top strategic acquirers in Gain Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Gain Therapeutics's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Gain Therapeutics?

Top strategic M&A buyers groups and sectors for Gain Therapeutics include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Gain Therapeutics's sector and industry vertical

Which are the top PE firms investing in Gain Therapeutics's sector and industry vertical?

Top PE firms investing in Gain Therapeutics's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Gain Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Gain Therapeutics's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Gain Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Gain Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Gain Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Gain Therapeutics?

The key public trading comparables and valuation benchmarks for Gain Therapeutics include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Gain Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Gain Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Gain Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Gain Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Gain Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Gain Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Gain Therapeutics

Start Free Trial Book a Demo